Received Jun 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 1 | — | OT |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | 2 | Y013274 | OT |
No additional AE reported; E-mail received in the MNSC Contact Center mailbox on 03JUN2025 at 9:14 PM with RMPDS after hours case MRK-2025-0063 reporting an AE for VAQTA. Verbatim: "This medical assistant reported that a "15 month old" patient received his first dose of VAQTA; This spontaneous report was received from a Medical Assistant and refers to a 16-year-old male patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 28-Feb-2025 (conflicting information as it was also reported as 28-Jan-2025), the patient was vaccinated with the first dose of Hepatitis A Vaccine, Inactivated (VAQTA),, dose number 1, 0.5 mL (0.5 mL), administered by Intramuscular route (lot # and expiration date were not reported). On 23-May-2025, the patient was vaccinated with the second dose of Hepatitis A Vaccine, Inactivated (VAQTA), (lot #Y013274, expiration date: 26-Dec-2025), dose number 2, 0.5 mL (0.5 mL), administered by Intramuscular route, both administered for prophylaxis, which was too early (inappropriate schedule of product administration). No adverse event was reported. Lot # for the first dose is being requested and will be submitted if received.